Hepatic Metastases
11
0
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Targeted Delivery of Chemotherapy With Ultrasound and Microbublles
Study of the Practice of Debiri in France
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases
the Efficacy and Safety of Sugammadex in Children 0-2 Years Old
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases